Home
Drugs
Fludarabine

Fludarabine

Drug

Drug Profile

Fludarabine is a purine analogue antineoplastic chemotherapy agent used for leukemia and lymphoma, including chronic lymphocytic leukemia. It is commonly administered as fludarabine phosphate by intravenous or oral routes. It was approved for medical use in the United States in 1991.

Drug Class: Purine analogue antimetabolite
Approval Status: Approved for medical use in the United States in 1991.
Mechanism of Action: Interferes with DNA duplication by inhibiting DNA synthesis through effects on ribonucleotide reductase and DNA polymerase.

Brand Names

Fludara
Oforta

Indications

\Chronic lymphocytic leukemia\
\Non-Hodgkin's lymphoma\
Leukemia

Related News

Off-the-Shelf CAR-T Therapy CB-011 Shows High Response Rates in Multiple Myeloma; Broader CAR-T Advances Presented at 2026 Tandem Meetings

Jun 09, 2026

Updated data from the phase I CaMMouflage trial showed CB-011, the first allogeneic anti-BCMA CAR-T therapy with immune cloaking, achieved an approximately 92% overall response rate in relapsed/refractory multiple myeloma. The 2026 Tandem Meetings also highlighted advances in EB-103, KITE-753, and LV20.19 CAR-T constructs across lymphoma and CLL. Separately, NXC-201 reported a 95% complete response rate in AL amyloidosis.

FDA Approves Calquence Plus Venetoclax as First All-Oral Fixed-Duration CLL Regimen

May 18, 2026

US FDA approved Calquence (acalabrutinib) plus venetoclax as the first all-oral, fixed-duration regimen for adults with chronic lymphocytic leukaemia and small lymphocytic lymphoma. Approval based on AMPLIFY phase III trial showing 77% progression-free at three years vs 67% with chemoimmunotherapy. Regimen already cleared in EU, UK, and Canada.

Soft Tissue Sarcoma Pipeline Highlights Phase II and Late-Stage Programs

May 12, 2026

Soft tissue sarcoma pipeline activity includes 70+ companies and 75+ therapies. A phase II ADI-PEG 20 trial with gemcitabine and docetaxel was designed for sarcomas, while other 2026 studies span synovial sarcoma and unresectable advanced disease.

Multiple Myeloma Pipeline Expands With 80+ Therapies as Treatment Paradigms Evolve

Mar 20, 2026

The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.

CAR T-Cell Therapies Target BCMA and Alternative Antigens in Multiple Myeloma

Feb 28, 2026

New CAR T-cell approaches targeting BCMA and CD19 simultaneously show encouraging early results, while researchers develop control strategies for CAR-T therapies including antibody-drug conjugates.

FDA Approves Acalabrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia

Feb 23, 2026

The FDA approved the combination of acalabrutinib and venetoclax as the first all-oral, fixed-duration regimen for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma, based on Phase 3 AMPLIFY trial results.

FDA Approves Calquence Plus Venetoclax as First All-Oral Fixed-Duration CLL Treatment

Feb 20, 2026

FDA approves AstraZeneca's Calquence plus venetoclax as first all-oral, 14-month fixed-duration regimen for first-line chronic lymphocytic leukemia, with 77% of patients progression-free at three years in Phase III trial.

FDA Approves Acalabrutinib Plus Venetoclax for First-Line CLL and SLL Treatment

Feb 20, 2026

The FDA has approved the combination of acalabrutinib and venetoclax as the first all-oral, fixed-duration BTK inhibitor-based regimen for previously untreated adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

FDA Approves Venclexta and Acalabrutinib Combination for Previously Untreated CLL Patients

Feb 20, 2026

The FDA has approved a supplemental new drug application for the combination regimen of Venclexta (venetoclax) and acalabrutinib for previously untreated adult patients with chronic lymphocytic leukemia, supported by Phase 3 AMPLIFY trial data.

FDA Approves Acalabrutinib Plus Venetoclax for Previously Untreated CLL

Feb 20, 2026

The FDA approved acalabrutinib plus venetoclax as the first all-oral, fixed-duration regimen for previously untreated chronic lymphocytic leukemia, based on phase III AMPLIFY trial results showing 35% reduction in disease progression or death risk versus chemoimmunotherapy.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07770802	Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer	NOT_YET_RECRUITING	PHASE1
NCT07764978	Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT	RECRUITING	PHASE3
NCT07759102	Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma	NOT_YET_RECRUITING	PHASE1
NCT07758673	Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma	NOT_YET_RECRUITING	PHASE1
NCT07737769	Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome	NOT_YET_RECRUITING	PHASE1
NCT07735637	A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).	NOT_YET_RECRUITING	PHASE3
NCT07720180	Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab	NOT_YET_RECRUITING	PHASE2
NCT07686107	Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML."	NOT_YET_RECRUITING	PHASE2
NCT07676877	Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma	NOT_YET_RECRUITING	PHASE1
NCT07672483	IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors	NOT_YET_RECRUITING	PHASE1